US Vitiligo Patients Experience Brief Treatment Durations and High Untreated Rates

Vitiligo is a chronic autoimmune condition that causes progressive skin depigmentation, often resulting in profound psychosocial distress and a diminished quality of life for affected patients [1, 2]. While the pathogenesis involves complex immune-mediated destruction of melanocytes, recent therapeutic advances have focused on modulating the Janus kinase pathway (a family of intracellular enzymes that mediate cytokine signaling) to arrest disease progression [3, 4]. Despite these developments, achieving repigmentation remains clinically difficult. Phase 3 trials of topical ruxolitinib 1.5% cream demonstrated that only 29.8% to 30.9% of patients achieved 75% facial repigmentation after 24 weeks of twice-daily application [3, 5]. Clinicians frequently rely on the Vitiligo Area Scoring Index (a standardized scale used to quantify the extent and degree of depigmentation) to monitor response, yet real-world management often deviates from controlled trial protocols [6, 7]. A retrospective cohort study of 24,949 patients now provides data on actual clinical practice in the United States, revealing that 27% to 32% of patients receive no treatment following their initial diagnosis [8].